Change of Registered Office

RNS Number : 2955G
Creo Medical Group PLC
28 February 2018
 

Creo Medical Group plc

 

Change of Registered Office

 

Chepstow, South Wales - 28 February 2018 - Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announces that it has changed its registered office address to Creo House, Unit 2 Beaufort Park, Beaufort Park Way, Chepstow, Wales NP16 5UH, with immediate effect.

 

Contacts

Creo Medical:

Cenkos:

FTI Consulting:

Richard Rees

+44 (0)129 160 6005

Richard.Rees@creomedical.com

Camilla Hume/Mark Connelly (NOMAD)

Michael Johnson / Russell Kerr (Sales)

+44 (0)207 397 8900

Brett Pollard / Mo Noonan

+44 (0)203 727 1000

creo@fticonsulting.com

 

About Creo Medical

 

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides physicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, www.creomedical.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CROQVLFLVLFLBBD
UK 100

Latest directors dealings